Please select the option that best describes you:

Do you prefer cisplatin or carboplatin in combination with nivolumab per CheckMate 816 for patients with resectable NSCLC?   

Based on subgroup analysis, do you have a preference for cisplatin over carboplatin? 



Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more